SK7162001A3 - Compositions comprising cefuroxime axetil - Google Patents
Compositions comprising cefuroxime axetil Download PDFInfo
- Publication number
- SK7162001A3 SK7162001A3 SK716-2001A SK7162001A SK7162001A3 SK 7162001 A3 SK7162001 A3 SK 7162001A3 SK 7162001 A SK7162001 A SK 7162001A SK 7162001 A3 SK7162001 A3 SK 7162001A3
- Authority
- SK
- Slovakia
- Prior art keywords
- cefuroxime axetil
- cefuroxime
- aqueous liquid
- axetil
- contact
- Prior art date
Links
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 title claims abstract description 243
- 229960002620 cefuroxime axetil Drugs 0.000 title claims abstract description 242
- 239000000203 mixture Substances 0.000 title description 33
- 239000007788 liquid Substances 0.000 claims abstract description 65
- 229920000642 polymer Polymers 0.000 claims abstract description 45
- 239000004480 active ingredient Substances 0.000 claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 claims abstract description 28
- 230000009246 food effect Effects 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 239000006104 solid solution Substances 0.000 claims abstract description 10
- 239000006186 oral dosage form Substances 0.000 claims abstract description 9
- 239000007962 solid dispersion Substances 0.000 claims abstract description 9
- 235000021471 food effect Nutrition 0.000 claims abstract description 8
- 230000002411 adverse Effects 0.000 claims abstract 4
- 239000003826 tablet Substances 0.000 claims description 84
- 239000008187 granular material Substances 0.000 claims description 54
- 239000000843 powder Substances 0.000 claims description 51
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 49
- 238000004090 dissolution Methods 0.000 claims description 45
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 45
- 239000003463 adsorbent Substances 0.000 claims description 35
- 239000002552 dosage form Substances 0.000 claims description 34
- 239000007941 film coated tablet Substances 0.000 claims description 34
- 229960001668 cefuroxime Drugs 0.000 claims description 33
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims description 33
- 239000000725 suspension Substances 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 21
- 239000006188 syrup Substances 0.000 claims description 20
- 235000020357 syrup Nutrition 0.000 claims description 20
- 239000011248 coating agent Substances 0.000 claims description 19
- 238000000576 coating method Methods 0.000 claims description 19
- 238000012360 testing method Methods 0.000 claims description 19
- 239000003960 organic solvent Substances 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 239000012736 aqueous medium Substances 0.000 claims description 7
- 238000009501 film coating Methods 0.000 claims description 5
- 239000007888 film coating Substances 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 230000000813 microbial effect Effects 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 claims 1
- -1 carboxy ester Chemical class 0.000 description 35
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 239000000945 filler Substances 0.000 description 16
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 16
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 16
- 239000000314 lubricant Substances 0.000 description 14
- 239000004094 surface-active agent Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000005469 granulation Methods 0.000 description 12
- 230000003179 granulation Effects 0.000 description 12
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 11
- 239000000454 talc Substances 0.000 description 11
- 229910052623 talc Inorganic materials 0.000 description 11
- 235000010980 cellulose Nutrition 0.000 description 10
- 229920002678 cellulose Polymers 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- 229930195725 Mannitol Natural products 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 8
- 239000000594 mannitol Substances 0.000 description 8
- 235000010355 mannitol Nutrition 0.000 description 8
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 229910002012 Aerosil® Inorganic materials 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 229930091371 Fructose Natural products 0.000 description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 6
- 239000005715 Fructose Substances 0.000 description 6
- 229920003083 Kollidon® VA64 Polymers 0.000 description 6
- 238000007922 dissolution test Methods 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000000227 grinding Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 6
- 238000001694 spray drying Methods 0.000 description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229950003588 axetil Drugs 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229940069328 povidone Drugs 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229960000913 crospovidone Drugs 0.000 description 4
- 230000002939 deleterious effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229920003091 Methocel™ Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 3
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000005056 compaction Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 2
- 244000303965 Cyamopsis psoralioides Species 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229910010413 TiO 2 Inorganic materials 0.000 description 2
- 229920013820 alkyl cellulose Polymers 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009477 fluid bed granulation Methods 0.000 description 2
- 239000008202 granule composition Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 229920006280 packaging film Polymers 0.000 description 2
- 239000012785 packaging film Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- LKDRXBCSQODPBY-ZXXMMSQZSA-N alpha-D-fructopyranose Chemical compound OC[C@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-ZXXMMSQZSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0198998A AT413647B (de) | 1998-11-26 | 1998-11-26 | Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten |
| PCT/EP1999/009096 WO2000030647A1 (en) | 1998-11-26 | 1999-11-24 | Compositions comprising cefuroxime axetil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK7162001A3 true SK7162001A3 (en) | 2001-10-08 |
Family
ID=3525440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK716-2001A SK7162001A3 (en) | 1998-11-26 | 1999-11-24 | Compositions comprising cefuroxime axetil |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6727243B1 (cs) |
| EP (1) | EP1133298B1 (cs) |
| JP (1) | JP2002530338A (cs) |
| KR (1) | KR20010080566A (cs) |
| CN (1) | CN1330546A (cs) |
| AR (1) | AR021405A1 (cs) |
| AT (3) | AT413647B (cs) |
| AU (1) | AU759517B2 (cs) |
| BR (1) | BR9915694A (cs) |
| CA (1) | CA2348876A1 (cs) |
| CO (1) | CO5190668A1 (cs) |
| CZ (1) | CZ20011845A3 (cs) |
| DE (1) | DE69935609T2 (cs) |
| ES (1) | ES2285866T3 (cs) |
| HU (1) | HUP0104412A3 (cs) |
| ID (1) | ID28615A (cs) |
| IL (1) | IL142762A0 (cs) |
| MY (1) | MY129564A (cs) |
| NO (1) | NO20012526D0 (cs) |
| NZ (1) | NZ511588A (cs) |
| PE (1) | PE20001326A1 (cs) |
| PL (1) | PL348744A1 (cs) |
| RU (1) | RU2248794C2 (cs) |
| SI (1) | SI1133298T1 (cs) |
| SK (1) | SK7162001A3 (cs) |
| TR (1) | TR200101417T2 (cs) |
| TW (1) | TWI229603B (cs) |
| WO (1) | WO2000030647A1 (cs) |
| YU (1) | YU34601A (cs) |
| ZA (1) | ZA200103927B (cs) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100342943B1 (ko) * | 1999-08-04 | 2002-07-02 | 민경윤 | 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물 |
| US7527807B2 (en) * | 2000-06-21 | 2009-05-05 | Cubist Pharmaceuticals, Inc. | Compositions and methods for increasing the oral absorption of antimicrobials |
| AU2001230490A1 (en) * | 2000-12-01 | 2002-06-11 | Arun Shriniwas Gosavi | Pharmaceutical formulation |
| EP1911462A3 (en) * | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
| US6524617B1 (en) * | 2001-07-25 | 2003-02-25 | Isp Investments Inc. | Synergistic filler composition |
| MY148466A (en) | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
| ES2201932B2 (es) * | 2001-11-23 | 2005-03-16 | Glaxo Group Limited | Composicion farmaceutica. |
| TW200404550A (en) * | 2002-07-08 | 2004-04-01 | Sankyo Co | Cepharospolin formulation for oral use |
| JP4526247B2 (ja) * | 2002-07-08 | 2010-08-18 | 第一三共株式会社 | 経口用セファロスポリン製剤 |
| WO2004019901A2 (en) * | 2002-08-30 | 2004-03-11 | Orchid Chemicals & Pharmaceuticals Ltd. | Sustained release pharmaceutical composition |
| WO2005002540A2 (en) * | 2003-07-01 | 2005-01-13 | Ranbaxy Laboratories Limited | Dry powder pharmaceutical suspension compositions of cefuroxime axetil |
| KR100552567B1 (ko) * | 2003-08-23 | 2006-02-15 | 한국유나이티드제약 주식회사 | 수분 흡수에 안정하고 빠르게 붕해되는 세푸록심 악세틸을포함하는 정제의 조성물 및 제조 방법 |
| NZ580951A (en) * | 2005-04-29 | 2011-06-30 | Cubist Pharm Inc | Therapeutic compositions |
| CN100402035C (zh) * | 2005-07-07 | 2008-07-16 | 石药集团中奇制药技术（石家庄）有限公司 | 一种微囊化头孢呋辛酯的药物组合物 |
| CA2800442C (en) | 2010-06-14 | 2018-05-22 | Ratiopharm Gmbh | Ivabradine-containing pharmaceutical composition with modified release |
| EP2882423A1 (en) * | 2012-08-07 | 2015-06-17 | Sandoz AG | Uncoated tablet comprising granules including a -lactam antibiotic and highly dispersed silicone dioxide |
| CA2910121A1 (en) | 2013-04-25 | 2014-10-30 | Kyorin Pharmaceutical Co., Ltd. | A pharmaceutical composition comprising a 1,4-dihydroquinoline carboxylic acid a cellulosic excipient and a salting-out agent |
| CN105338982B (zh) | 2013-04-25 | 2017-10-10 | 杏林制药株式会社 | 固体药用组合物 |
| JP6018334B2 (ja) | 2014-10-23 | 2016-11-02 | 杏林製薬株式会社 | 固形医薬組成物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1571683A (en) * | 1976-02-16 | 1980-07-16 | Glaxo Operations Ltd | Ester derivatives of cefuroxime |
| GB1572993A (en) * | 1976-02-16 | 1980-08-13 | Glaxo Operations Ltd | Ester derivatives of cefuroxime |
| YU44680B (en) * | 1982-07-30 | 1990-12-31 | Glaxo Lab Ltd | Process for obtaining very pure amorphous form of cephuroxim axetile |
| GB8524001D0 (en) * | 1985-09-30 | 1985-11-06 | Glaxo Group Ltd | Pharmaceutical composition |
| ZA881301B (en) * | 1987-02-27 | 1989-10-25 | Lilly Co Eli | Sustained release matrix formulations |
| NL193682C (nl) * | 1987-05-14 | 2000-07-04 | Glaxo Group Ltd | Beklede cefuroximaxetilsamenstelling. |
| DE3810343A1 (de) * | 1988-03-26 | 1989-10-05 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen retardformen |
| DE4139963A1 (de) * | 1991-12-04 | 1993-06-09 | Basf Ag, 6700 Ludwigshafen, De | Redispergierbares dispersionspulver aus n-vinylpyrrolidon-vinylacetat-copolymerisat, dessen herstellung und verwendung |
| DE19602757A1 (de) * | 1996-01-26 | 1997-07-31 | Boehringer Mannheim Gmbh | Feste Instant-Release-Darreichungsformen und Verfahren zu ihrer Herstellung |
| US5663258A (en) * | 1996-02-20 | 1997-09-02 | Isp Investments Inc. | Strongly swellable, moderately crosslinked copolymers of vinylpyrrolidone and vinyl acetate |
| DE19631085A1 (de) * | 1996-08-01 | 1998-02-05 | Basf Ag | Verwendung von (Meth)acrylsäure-Maleinsäure-Copolymeren zur Verbesserung der Permeabilität der Schleimhaut |
| ES2565163T3 (es) * | 1996-10-28 | 2016-03-31 | General Mills, Inc. | Imbibición y encapsulación de partículas de liberación controlada y producto encapsulado |
| IL119627A (en) * | 1996-11-17 | 2002-03-10 | Yissum Res Dev Co | PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT |
| CA2209868C (en) * | 1997-08-15 | 2001-08-14 | Bernard Charles Sherman | Pharmaceutical compositions comprising cefuroxime axetil |
| EP1066040B1 (en) * | 1998-03-03 | 2003-02-19 | Daewoong Pharmaceutical Co., Ltd. | Pharmaceutical composition containing cefuroxime axetil stable for moisture absorption |
| CA2239331C (en) * | 1998-05-29 | 1999-11-30 | Bernard Charles Sherman | Pharmaceutical tablets comprising cefuroxime axetil |
| DE19835823A1 (de) * | 1998-08-10 | 1999-10-07 | Lindopharm Gmbh | Pharmazeutische Zusammensetzung, Verfahren zu ihrer Herstellung und ihre Verwendung sowie aus ihr hergestellte wässerige Suspension |
| KR100342943B1 (ko) | 1999-08-04 | 2002-07-02 | 민경윤 | 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물 |
-
1998
- 1998-11-26 AT AT0198998A patent/AT413647B/de not_active IP Right Cessation
-
1999
- 1999-11-20 TW TW088120315A patent/TWI229603B/zh not_active IP Right Cessation
- 1999-11-24 TR TR2001/01417T patent/TR200101417T2/xx unknown
- 1999-11-24 NZ NZ511588A patent/NZ511588A/en unknown
- 1999-11-24 SK SK716-2001A patent/SK7162001A3/sk unknown
- 1999-11-24 US US09/445,741 patent/US6727243B1/en not_active Expired - Fee Related
- 1999-11-24 CN CN99813759A patent/CN1330546A/zh active Pending
- 1999-11-24 EP EP99959327A patent/EP1133298B1/en not_active Expired - Lifetime
- 1999-11-24 CA CA002348876A patent/CA2348876A1/en not_active Abandoned
- 1999-11-24 ES ES99959327T patent/ES2285866T3/es not_active Expired - Lifetime
- 1999-11-24 DE DE69935609T patent/DE69935609T2/de not_active Expired - Lifetime
- 1999-11-24 PL PL99348744A patent/PL348744A1/xx unknown
- 1999-11-24 IL IL14276299A patent/IL142762A0/xx unknown
- 1999-11-24 HU HU0104412A patent/HUP0104412A3/hu unknown
- 1999-11-24 WO PCT/EP1999/009096 patent/WO2000030647A1/en active IP Right Grant
- 1999-11-24 JP JP2000583530A patent/JP2002530338A/ja not_active Withdrawn
- 1999-11-24 BR BR9915694-6A patent/BR9915694A/pt not_active IP Right Cessation
- 1999-11-24 RU RU2001117518/15A patent/RU2248794C2/ru not_active IP Right Cessation
- 1999-11-24 KR KR1020017006542A patent/KR20010080566A/ko not_active Ceased
- 1999-11-24 AT AT99959327T patent/ATE357237T1/de active
- 1999-11-24 SI SI9930969T patent/SI1133298T1/sl unknown
- 1999-11-24 CZ CZ20011845A patent/CZ20011845A3/cs unknown
- 1999-11-24 ID IDW00200101088A patent/ID28615A/id unknown
- 1999-11-24 AU AU16544/00A patent/AU759517B2/en not_active Ceased
- 1999-11-24 YU YU34601A patent/YU34601A/sh unknown
- 1999-11-25 AR ARP990106024A patent/AR021405A1/es not_active Application Discontinuation
- 1999-11-25 PE PE1999001186A patent/PE20001326A1/es not_active Application Discontinuation
- 1999-11-26 CO CO99074648A patent/CO5190668A1/es not_active Application Discontinuation
- 1999-11-26 MY MYPI99005158A patent/MY129564A/en unknown
-
2001
- 2001-05-15 ZA ZA200103927A patent/ZA200103927B/en unknown
- 2001-05-23 NO NO20012526A patent/NO20012526D0/no not_active Application Discontinuation
-
2004
- 2004-02-23 AT AT0028104A patent/AT500135A1/de not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2258841C (en) | Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug | |
| KR100767928B1 (ko) | 활성 성분의 맛이 차폐되고 활성 성분이 즉시 방출되는 코팅된 과립의 제조 방법 | |
| SK7162001A3 (en) | Compositions comprising cefuroxime axetil | |
| CA2272586C (en) | Rapidly disintegrable pharmaceutical composition | |
| EP1341527B1 (en) | Pharmaceutical preparation comprising an active dispersed on a matrix | |
| US20220105131A1 (en) | Pharmaceutical compositions | |
| TWI228414B (en) | Pharmaceutical composition comprising carvedilol and hydrochlorothiazide, solid dosage form comprising it, and process for the production of the same | |
| UA81781C2 (uk) | Фармацевтична композиція, яка включає телмісартан, спосіб її одержання (варіанти), двошарова фармацевтична таблетка та спосіб її одержання | |
| HU226492B1 (en) | Enteric coated pharmaceutical tablet containing didanoside | |
| CZ20021765A3 (cs) | Způsob potahování jader tablet a tablety tímto způsobem získané | |
| JPH05246861A (ja) | ポリカルボフィルカルシウム含有製剤 | |
| CA2253769C (en) | Pharmaceutical compositions comprising fenofibrate | |
| KR0133526B1 (ko) | Nb-818의 용이흡수성 약제 | |
| KR20000015865A (ko) | 칼륨, 나트륨 및 트리스옥사프로진염의 약학적 제제 | |
| JP3836893B2 (ja) | ポリカルボフィルカルシウム含有製剤 | |
| JP2000516601A (ja) | 水溶性化合物及びセルロースを含有する粒状物 | |
| KR100464210B1 (ko) | 세푸록심 악세틸 함유 약제학적 조성물 및 그의 제조방법 | |
| WO1999020277A1 (fr) | Composition medicamenteuse a dissolution rapide | |
| MXPA01005274A (en) | Compositions comprising cefuroxime axetil | |
| AU3341301A (en) | Pharmaceutical formulations comprising amoxocyllin and clavulanate |